Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

QbD Based Development and Validation of RP-HPLC Method for Nintedanib Esylate: Application to Bioanalytical and Stability Study in Plasma

QbD Based Development and Validation of RP-HPLC Method for Nintedanib Esylate: Application to... Abstract The objective of this experiment was to develop and validate a simple, robust, and accurate Reverse- Phase High-Performance Liquid Chromatography method for estimation of Nintedanib Esylate in bulk, Pharmaceutical Dosage form, and Human Plasma. Full 3 Level Factorial design was employed for optimizing columns C8 and C18. The optimized chromatographic conditions are column C18, Ammonium format buffer: Acetonitrile (28.19:71.81 v/v) and pH of buffer (3). Furthermore, acetonitrile was used as a precipitating agent to extract Nintedanib in human plasma. After centrifuging at 2000 rpm, the supernatant was then injected and observed that the peak from blank plasma does not interfere with the peak of Nintedanib by using p-nitrophenol as an internal standard. Linearity was observed in the concentration range of 10 µg to 50 µg/mL (r2=0.9988). The accuracy range was 99.87 to 100.08 %. Intra-day and Inter-day precision was found to be 0.5432 & 0.5242 (% RSD). The bioanalytical method was validated as per ICH guideline M10 and results were found to be r2 (0.9988), Recovery (99.91 %), Specificity (99.94 %), Precision (Less than 0.543 % RSD), and Robustness (less than 0.500 % RSD. The proposed method was useful for the best analysis of Nintedanib Esylate in Bulk, pharmaceutical dosage forms and was successfully applied to a pharmacokinetic study. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Analytical Chemistry Letters Taylor & Francis

QbD Based Development and Validation of RP-HPLC Method for Nintedanib Esylate: Application to Bioanalytical and Stability Study in Plasma

Waghmare, Santosh. A.; Sumithra, M.
Analytical Chemistry Letters , Volume 11 (3): 17 – May 4, 2021
Download PDF

QbD Based Development and Validation of RP-HPLC Method for Nintedanib Esylate: Application to Bioanalytical and Stability Study in Plasma

Abstract

Abstract The objective of this experiment was to develop and validate a simple, robust, and accurate Reverse- Phase High-Performance Liquid Chromatography method for estimation of Nintedanib Esylate in bulk, Pharmaceutical Dosage form, and Human Plasma. Full 3 Level Factorial design was employed for optimizing columns C8 and C18. The optimized chromatographic conditions are column C18, Ammonium format buffer: Acetonitrile (28.19:71.81 v/v) and pH of buffer (3). Furthermore, acetonitrile was...
Loading next page...
 
/lp/taylor-francis/qbd-based-development-and-validation-of-rp-hplc-method-for-nintedanib-7EDCUuKjIp
Publisher
Taylor & Francis
Copyright
© 2021 Har Krishan Bhalla & Sons
ISSN
2230-7532
eISSN
2229-7928
DOI
10.1080/22297928.2021.1930581
Publisher site
See Article on Publisher Site

Abstract

Abstract The objective of this experiment was to develop and validate a simple, robust, and accurate Reverse- Phase High-Performance Liquid Chromatography method for estimation of Nintedanib Esylate in bulk, Pharmaceutical Dosage form, and Human Plasma. Full 3 Level Factorial design was employed for optimizing columns C8 and C18. The optimized chromatographic conditions are column C18, Ammonium format buffer: Acetonitrile (28.19:71.81 v/v) and pH of buffer (3). Furthermore, acetonitrile was used as a precipitating agent to extract Nintedanib in human plasma. After centrifuging at 2000 rpm, the supernatant was then injected and observed that the peak from blank plasma does not interfere with the peak of Nintedanib by using p-nitrophenol as an internal standard. Linearity was observed in the concentration range of 10 µg to 50 µg/mL (r2=0.9988). The accuracy range was 99.87 to 100.08 %. Intra-day and Inter-day precision was found to be 0.5432 & 0.5242 (% RSD). The bioanalytical method was validated as per ICH guideline M10 and results were found to be r2 (0.9988), Recovery (99.91 %), Specificity (99.94 %), Precision (Less than 0.543 % RSD), and Robustness (less than 0.500 % RSD. The proposed method was useful for the best analysis of Nintedanib Esylate in Bulk, pharmaceutical dosage forms and was successfully applied to a pharmacokinetic study.

Journal

Analytical Chemistry Letters – Taylor & Francis

Published: May 4, 2021

Keywords: Nintedanib Esylate; Bioanalytical Method; RP-HPLC; 3 Level Factorial design; QbD; Idiopathic

References

  • Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients
  • Nintedanib-cyclodextrin complex to improve bio-activity and intestinal permeability
  • Interplay of multiple interaction forces: Binding of tyrosine kinase inhibitor nintedanib with human serum albumin. J
  • Validated RP-HPLC Method for Determination and Quantification of Nintedanib in Pharmaceutical Formulation
  • Development and validation of a simple and sensitive stability-indicating RP-HPLC assay method for determination of Nintedanib and stress degradation studies
  • Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
  • pH-dependent solubility and permeability profiles: A useful tool for prediction of oral bioavailability
  • Quality by Design as a risk-based strategy in pharmaceutical analysis: Development of a liquid chromatography-tandem mass spectrometry method for the determination of nintedanib and its impurities
  • QbD-mediated RP-UPLC method development invoking an FMEA-based risk assessment to estimate nintedanib degradation products and their pathways
  • Development and Validation of HPLC method for simultaneous estimation of Rifampicin and Ofloxacin using experimental design
  • An overview of experimental designs in HPLC method development and validation
  • Stability- indicating RP-HPLC method development and validation for determination of nine impurities in apixaban tablet dosage forms. Robustness study by quality by design approach
  • Quality by design (QbD)-based development and optimization of a simple, robust RP-HPLC method for the estimation of methotrexate
  • A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology
  • Ultra-high per- formance liquid chromatography-MS/MS (UHPLC-MS/MS) in practice: analysis of drugs and pharmaceutical formulations
  • A review on bio- analytical method development and validation by RP-HPLC
  • Bioanalytical method development and validation of sitagliptin phosphate by RP-HPLC and its application to pharmacokinetic study. Int
  • Bioanalytical method development and validation of vildagliptin a novel dipeptidyl peptidase IV inhibitor by RP-HPLC method
  • Bioanalytical method development and validation of Lamivudine by RP-HPLC method
  • Bioanalytical method development and validation of ticagrelor by RP-HPLC
  • Bioanalytical method development and validation for simultaneous estimation of cefixime and dicloxacillin by RP-HPLC in human plasma
  • Simultaneous determination of nintedanib and its metabolite by UPLC-MS/MS in rat plasma and its application to a pharmacokinetic study
  • Development and validation of UPLC/ESI-Q- TOF-MS for carteolol in aqueous humor: Stability, stress degradation, and application in the pharmacokinetics of nanoformulation
  • Quality by design (QbD) based development and validation of bioanalytical RP-HPLC method for dapagliflozin: Forced degradation and preclinical pharmacokinetic study